Download The Lancet – Volume 377, Number 9759 (2011 - January - 1) by Richard Horton PDF

By Richard Horton

Show description

Read Online or Download The Lancet – Volume 377, Number 9759 (2011 - January - 1) PDF

Similar nonfiction_2 books

Beyond the Wire: Former Prisoners and Conflict Transformation in No

This booklet offers the 1st specific exam of the function performed by means of former loyalist and republican prisoners in grass roots clash transformation paintings within the Northern eire peace method. It demanding situations the assumed passivity of former prisoners and ex-combatants. as a substitute, it means that such members and the teams which they shaped were key brokers of clash transformation.

Savoring: A New Model of Positive Experience

This publication is set savoring life—the capability to take care of the fun, pleasures, and different optimistic emotions that we event in our lives. The authors increase our knowing of what savoring is and the stipulations lower than which it happens. Savoring presents a brand new theoretical version for conceptualizing and knowing the psychology of pleasure and the procedures by which humans deal with confident feelings.

Where EGOs Dare: The Untold Truth About Narcissistic Leaders - and How to Survive Them

Management. The note inspires photographs of dynamic motion, inspiring imaginative and prescient and a hugely stimulated crew. the nice leaders of trade are the idols of our time. yet what of the Demon chief, the damaging strength, the bully within the boardroom? we have heard much approximately confident management yet what concerning the darkish aspect -- the narcissistic chief?

Extra info for The Lancet – Volume 377, Number 9759 (2011 - January - 1)

Example text

In three large UK trials, long-term post-trial follow-up of individual patients was obtained from death certificates and cancer registries. See Comment page 3 Results In eight eligible trials (25 570 patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer (pooled odds ratio [OR] 0·79, 95% CI 0·68–0·92, p=0·003). On analysis of individual patient data, which were available from seven trials (23 535 patients, 657 cancer deaths), benefit was apparent only after 5 years’ follow-up (all cancers, hazard ratio [HR] 0·66, 0·50–0·87; gastrointestinal cancers, 0·46, 0·27–0·77; both p=0·003).

In three large UK trials, long-term post-trial follow-up of individual patients was obtained from death certificates and cancer registries. See Comment page 3 Results In eight eligible trials (25 570 patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer (pooled odds ratio [OR] 0·79, 95% CI 0·68–0·92, p=0·003). On analysis of individual patient data, which were available from seven trials (23 535 patients, 657 cancer deaths), benefit was apparent only after 5 years’ follow-up (all cancers, hazard ratio [HR] 0·66, 0·50–0·87; gastrointestinal cancers, 0·46, 0·27–0·77; both p=0·003).

Benefit was unrelated to aspirin dose (75 mg upwards), sex, or smoking, but increased with age—the absolute reduction in 20-year risk of cancer death reaching 7·08% (2·42–11·74) at age 65 years and older. Interpretation Daily aspirin reduced deaths due to several common cancers during and after the trials. Benefit increased with duration of treatment and was consistent across the different study populations. These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention.

Download PDF sample

Rated 4.36 of 5 – based on 20 votes